The US FDA has granted fast track designation to the novel amanitin-based antibody-drug conjugate (ADC) pamlectabart ...
About Mondego Bio Mondego Bio, headquartered at Portugal's Biocant biotech park, is developing best-in-class PTPN2 inhibitors as a next-generation immuno-oncology strategy. The company's Series A ...
Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for ...
India: Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced ...
In the rapidly evolving pharmaceutical landscape, drug discovery services have become a pivotal axis around which innovation, efficiency and competitiveness rotate. According to a recent market report ...
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...
Elevara Medicines secured $70 million in Series A funding to advance ELV001's Phase II trial for rheumatoid arthritis and explore other chronic inflammatory conditions. Pharma investments surge as ...
Ventus Therapeutics enters agreement with Genentech to discover and develop small-molecule medicines using Ventus’ ReSOLVE platform: Waltham, Massachusetts Thursday, October 23, ...
The large-mass animal crossover bioequivalence study will commence in the next two to three weeks and will be carried out ...
Given the critical importance of endocytosis detection in ADC research and development, ACROBiosystems has designed an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback